On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra is for those patients who have failed to respond to other therapies that cure leukemia. This new drug marketed by GSK was originally developed by GlaxoSmithKline and Genmab A/S, a Danish company. The drug is designed to treat patients with chronic lymphocytic leukemia also known as CLL and for those whose disease has progressed despite previous treatments with other cancer drugs.

GSK is a global healthcare company that is more into the creation and development, manufacturing and marketing of various pharmaceutical products including vaccines and over the counter medicines and other health related

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 23, 2009

DrStockPick.com Stock Report!

GENZ, PWRM, STEM, CTIC, PFE

**************************************************************

GENZ, Genzyme Corporation

GENZ is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.

GENZ provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these products. GENZ is now approximately half-way through the anticipated shortage period

...

QuantRx Biomedical Corp. is a diagnostics company engaged in the development and commercialization of innovative diagnostic products centered on its patented technology platforms. Friday, the company announced its joint venture with NuRx Pharmaceuticals Inc. (NUXP.OB), a life sciences company engaged in the research and development of oncology products and relative care.

The joint venture was formed to accelerate efforts to take advantage of Point-of-Care (POC) products. Per the agreement, NuRx will provide the new venture, QN Diagnostics LLC, with more than $5 million of working capital, which will be used for marketing and revenue generation of its POC line of products.

Equally owned by QuantRx and NuRx, QN Diagnostics is supported by 30 years of diagnostic healthcare research and development expertise, and will move the companies forward in the market. “The formation of QN Diagnostics is an extraordinary milestone for QuantRx, its shareholders and the global healthcare community,” Walter Witoshkin,

...

Angiodynamics, Inc. (ANGO) reported fourth quarter and full fiscal year 2009 results and provided guidance for full fiscal year 2010 yesterday after the close of the market. Excluding extraordinary items, the company reported fourth quarter EPS of $0.14, below the Street’s expectations of $0.15. The company also provided guidance for fiscal 2010 below the Street’s expectations. Quarterly results Net sales in the quarter were $52.8 million, an increase of 13% y/y. Growth in net sales can be attributed to higher sales of vein ablation and oncology products, primarily the company’s embolization product, LCB. Peripheral Vascular sales increased 26% y/y to $22.5 million. Growth was primarily due to the acquisition of laser ablation products from Diomed and the Benephit renal infusion system from FlowMedica. Access sales declined 1% y/y to $17.9 million. The decline was due to the withdrawal of the Centros dialysis catheter from the ...

ADVENTRX Pharmaceuticals, Inc. announced that it has granted Shin Poong Pharmaceutical Co., Ltd. (SEO: 019170.KS) the exclusive rights to make, use and sell ANX-514 (docetaxel emulsion), one of its two lead product candidates, in South Korea. In exchange, ADVENTRX will receive an upfront cash payment of $300,000, up to approx. $2 million in regulatory and commercial milestones, and royalties on net sales of licensed products.

“Shin Poong is well-positioned to successfully develop and commercialize ANX-514 in South Korea,” commented Brian M. Culley, Chief Business Officer of ADVENTRX. “Established in 1962, Shin Poong has grown to more than 1,500 employees. They are a leader in this territory, with expertise in clinical development, as well as a dedicated business unit focused on the sales and marketing of oncology products.”

“We are excited about this first validation of our detergent-free docetaxel program, and we remain committed to finding additional partners for ANX-514, as well

...